The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma

1. Auer K, Bachmayr-Heyda A, Sukhbaatar N, Aust S, Schmetterer KG, Meier SM, et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget 2016; 7: 61336–54. doi: 10.18632/oncotarget.11038 AuerK Bachmayr-HeydaA SukhbaatarN AustS SchmettererKG MeierSM Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer Oncotarget 2016 7 61336 54 10.18632/oncotarget.11038 Open DOISearch in Google Scholar

2. Wefers C, Duiveman-de Boer T, Yigit R, Zusterzeel PLM, van Altena AM, Massuger LFAG, et al. Survival of ovarian cancer patients is independent of the presence of DC and T cell subsets in ascites. Front Immunol 2019; 11: 3156–65. doi: 10.3389/fimmu.2018.03156 WefersC Duiveman-de BoerT YigitR ZusterzeelPLM van AltenaAM MassugerLFAG Survival of ovarian cancer patients is independent of the presence of DC and T cell subsets in ascites Front Immunol 2019 11 3156 65 10.3389/fimmu.2018.03156 Open DOISearch in Google Scholar

3. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 2005; 16(Suppl 8): viii7–12. doi: 10.1093/annonc/mdi961 du BoisA QuinnM ThigpenT VermorkenJ Avall-LundqvistE BookmanM 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004) Ann Oncol 2005 16 Suppl 8 viii7 12 10.1093/annonc/mdi961 Open DOISearch in Google Scholar

4. Zhu C, Xu Z, Zhang T, Qian L, Xiao W, Wei H, et al. Updates of pathogenesis, diagnostic and therapeutic perspectives for ovarian clear cell carcinoma. J Cancer 2021; 12: 2295–316. doi: 10.7150/jca.53395 ZhuC XuZ ZhangT QianL XiaoW WeiH Updates of pathogenesis, diagnostic and therapeutic perspectives for ovarian clear cell carcinoma J Cancer 2021 12 2295 316 10.7150/jca.53395 Open DOISearch in Google Scholar

5. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203–13. doi: 10.1056/NEJMoa020177 ZhangL Conejo-GarciaJR KatsarosD GimottyPA MassobrioM RegnaniG Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 2003 348 203 13 10.1056/NEJMoa020177 Open DOISearch in Google Scholar

6. Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 2014; 20: 434–44. doi: 10.1158/1078-0432.CCR-13-1877 WebbJR MilneK WatsonP DeleeuwRJ NelsonBH Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer Clin Cancer Res 2014 20 434 44 10.1158/1078-0432.CCR-13-1877 Open DOISearch in Google Scholar

7. Gupta P, Chen C, Chaluvally-Raghavan P, Pradeep SB. Cells as an immune-regulatory signature in ovarian cancer. Cancers 2019; 11: 894–903. doi: 10.3390/cancers11070894 GuptaP ChenC Chaluvally-RaghavanP PradeepSB Cells as an immune-regulatory signature in ovarian cancer Cancers 2019 11 894 903 10.3390/cancers11070894 Open DOISearch in Google Scholar

8. Gupta V, Yull F, Khabele D. Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy. Cancers 2018; 10: 366–98. doi: 10.3390/cancers10100366 GuptaV YullF KhabeleD Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy Cancers 2018 10 366 98 10.3390/cancers10100366 Open DOISearch in Google Scholar

9. Piętak P, Pietrzyk N, Pawłowska A, Suszczyk D, Bednarek W, Kotarski J, et al. The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis. Wiad Lek 2018; 71: 1089–94. PiętakP PietrzykN PawłowskaA SuszczykD BednarekW KotarskiJ The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis Wiad Lek 2018 71 1089 94 Search in Google Scholar

10. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, et al. The ratios of CD8⁺ T cells to CD4⁺CD25⁺ FOXP3⁺ and FOXP3⁻ T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One 2013; 8: e80063. doi: 10.1371/journal.pone.0080063 PrestonCC MaurerMJ ObergAL VisscherDW KalliKR HartmannLC The ratios of CD8⁺ T cells to CD4⁺CD25⁺ FOXP3⁺ and FOXP3⁻ T cells correlate with poor clinical outcome in human serous ovarian cancer PLoS One 2013 8 e80063 10.1371/journal.pone.0080063 Open DOISearch in Google Scholar

11. Nakano M, Ito M, Tanaka R, Yamaguchi K, Ariyama H, Mitsugi K, et al. PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer. Cancer Sci 2018; 109: 2986–92. doi: 10.1111/cas.13723 NakanoM ItoM TanakaR YamaguchiK AriyamaH MitsugiK PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer Cancer Sci 2018 109 2986 92 10.1111/cas.13723 Open DOISearch in Google Scholar

12. Miceska S, Škof E, Novaković S, Stegel V, Jeričević A, Grčar Kuzmanov B, et al. Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites. Cancer Cytopathol 2023; 131: 188–97. doi: 10.1002/cncy.22664 MiceskaS ŠkofE NovakovićS StegelV JeričevićA Grčar KuzmanovB Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites Cancer Cytopathol 2023 131 188 97 10.1002/cncy.22664 Open DOISearch in Google Scholar

13. Brozic A, Pohar Marinsek Z, Novakovic S, Kloboves Prevodnik V. Inconclusive flow cytometric surface light chain results can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015; 20: 191–201. doi: 10.1186/s13000-015-0427-5 BrozicA Pohar MarinsekZ NovakovicS Kloboves PrevodnikV Inconclusive flow cytometric surface light chain results can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015 20 191 201 10.1186/s13000-015-0427-5 Open DOISearch in Google Scholar

14. Hoogstad-van Evert JS, Bekkers R, Ottevanger N, Jansen JH, Massuger L, Dolstra H. Harnessing natural killer cells for the treatment of ovarian cancer. Gynecol Oncol 2020; 157: 810–6. doi: 10.1016/j.ygyno.2020.03.020 Hoogstad-van EvertJS BekkersR OttevangerN JansenJH MassugerL DolstraH Harnessing natural killer cells for the treatment of ovarian cancer Gynecol Oncol 2020 157 810 6 10.1016/j.ygyno.2020.03.020 Open DOISearch in Google Scholar

15. Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer 2020; 123: 9–16. doi: 10.1038/s41416-020-0875-x FordCE WernerB HackerNF WartonK The untapped potential of ascites in ovarian cancer research and treatment Br J Cancer 2020 123 9 16 10.1038/s41416-020-0875-x Open DOISearch in Google Scholar

16. Sato S, Matsushita H, Shintani D, Kobayashi Y, Fujieda N, Yabuno A, et al. Association between effector-type regulatory T cells and immune checkpoint expression on CD8⁺ T cells in malignant ascites from epithelial ovarian cancer. BMC Cancer 2022; 22: 437–45. doi: 10.1186/s12885-022-09534-z SatoS MatsushitaH ShintaniD KobayashiY FujiedaN YabunoA Association between effector-type regulatory T cells and immune checkpoint expression on CD8⁺ T cells in malignant ascites from epithelial ovarian cancer BMC Cancer 2022 22 437 45 10.1186/s12885-022-09534-z Open DOISearch in Google Scholar

17. Steitz AM, Steffes A, Finkernagel F, Unger A, Sommerfeld L, Jansen JM, et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis 2020; 11: 249–63. doi: 10.1038/s41419-020-2438-8 SteitzAM SteffesA FinkernagelF UngerA SommerfeldL JansenJM Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C Cell Death Dis 2020 11 249 63 10.1038/s41419-020-2438-8 Open DOISearch in Google Scholar

18. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64: 5535–8. doi: 10.1158/0008-5472.CAN-04-1272 CurielTJ ChengP MottramP AlvarezX MoonsL Evdemon-HoganM Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer Cancer Res 2004 64 5535 8 10.1158/0008-5472.CAN-04-1272 Open DOISearch in Google Scholar

19. Almeida-Nunes DL, Mendes-Frias A, Silvestre R, Dinis-Oliveira RJ, Ricardo S. Immune tumor microenvironment in ovarian cancer ascites. Int J Mol Sci 2022; 23: 10692–714. doi: 10.3390/ijms231810692 Almeida-NunesDL Mendes-FriasA SilvestreR Dinis-OliveiraRJ RicardoS Immune tumor microenvironment in ovarian cancer ascites Int J Mol Sci 2022 23 10692 714 10.3390/ijms231810692 Open DOISearch in Google Scholar

20. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8⁺ tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538–43. doi: 10.1073/pnas.0509182102 SatoE OlsonSH AhnJ BundyB NishikawaH QianF Intraepithelial CD8⁺ tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci U S A 2005 102 18538 43 10.1073/pnas.0509182102 Open DOISearch in Google Scholar

21. Ning F, Cole CB, Annunziata CM. Driving immune responses in the ovarian tumor microenvironment. Front Oncol 2021; 10: 604084. doi: 10.3389/fonc.2020.604084 NingF ColeCB AnnunziataCM Driving immune responses in the ovarian tumor microenvironment Front Oncol 2021 10 604084 10.3389/fonc.2020.604084 Open DOISearch in Google Scholar

22. Singh M, Loftus T, Webb E, Benencia F. Minireview: regulatory T cells and ovarian cancer. Immunol Invest 2016; 45: 712–20. doi: 10.1080/08820139.2016.1186689 SinghM LoftusT WebbE BenenciaF Minireview: regulatory T cells and ovarian cancer Immunol Invest 2016 45 712 20 10.1080/08820139.2016.1186689 Open DOISearch in Google Scholar

23. Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, et al. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother 2015; 64: 1495–504. doi: 10.1007/s00262-015-1753-x KnutsonKL MaurerMJ PrestonCC MoysichKB GoergenK HawthorneKM Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer Cancer Immunol Immunother 2015 64 1495 504 10.1007/s00262-015-1753-x Open DOISearch in Google Scholar

24. Hoffmann JC, Schön MP. Integrin α_E(CD103)β₇ in epithelial cancer. Cancers 2021; 13: 6211–29. doi: 10.3390/cancers13246211 HoffmannJC SchönMP Integrin α_E(CD103)β₇ in epithelial cancer Cancers 2021 13 6211 29 10.3390/cancers13246211 Open DOISearch in Google Scholar

25. Laumont CM, Wouters MCA, Smazynski J, Gierc NS, Chavez EA, Chong LC, et al. Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer. Clin Cancer Res 2021; 27: 4089–100. doi: 10.1158/1078-0432.CCR-20-4394 LaumontCM WoutersMCA SmazynskiJ GiercNS ChavezEA ChongLC Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer Clin Cancer Res 2021 27 4089 100 10.1158/1078-0432.CCR-20-4394 Open DOISearch in Google Scholar

26. Webb JR, Wick DA, Nielsen JS, Tran E, Milne K, McMurtrie E, et al. Profound elevation of CD8⁺ T cells expressing the intraepithelial lymphocyte marker CD103 (alpha_E/beta₇ Integrin) in high-grade serous ovarian cancer. Gynecol Oncol 2010; 118: 228–36. doi: 10.1016/j.ygyno.2010.05.016 WebbJR WickDA NielsenJS TranE MilneK McMurtrieE Profound elevation of CD8⁺ T cells expressing the intraepithelial lymphocyte marker CD103 (alpha_E/beta₇ Integrin) in high-grade serous ovarian cancer Gynecol Oncol 2010 118 228 36 10.1016/j.ygyno.2010.05.016 Open DOISearch in Google Scholar

27. Bösmüller HC, Wagner P, Peper JK, Schuster H, Pham DL, Greif K, et al. Combined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer. Int J Gynecol Cancer 2016; 26: 671–9. doi: 10.1097/IGC.0000000000000672 BösmüllerHC WagnerP PeperJK SchusterH PhamDL GreifK Combined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer Int J Gynecol Cancer 2016 26 671 9 10.1097/IGC.0000000000000672 Open DOISearch in Google Scholar

28. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006; 125: 451–8. DongHP ElstrandMB HolthA SilinsI BernerA TropeCG NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma Am J Clin Pathol 2006 125 451 8 Search in Google Scholar

29. Wei X, Jin Y, Tian Y, Zhang H, Wu J, Lu W, et al. Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumour Biol 2016; 37: 6581–8. doi: 10.1007/s13277-015-4538-0 WeiX JinY TianY ZhangH WuJ LuW Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients Tumour Biol 2016 37 6581 8 10.1007/s13277-015-4538-0 Open DOISearch in Google Scholar

30. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20⁺ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8⁺ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012; 18: 3281–92. doi: 10.1158/1078-0432.CCR-12-0234 NielsenJS SahotaRA MilneK KostSE NesslingerNJ WatsonPH CD20⁺ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8⁺ T cells promote favorable prognosis in ovarian cancer Clin Cancer Res 2012 18 3281 92 10.1158/1078-0432.CCR-12-0234 Open DOISearch in Google Scholar

31. Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer 2018; 6: 139–51. doi: 10.1186/s40425-018-0446-3 TruxovaI KasikovaL HenslerM SkapaP LacoJ PecenL Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients J Immunother Cancer 2018 6 139 51 10.1186/s40425-018-0446-3 Open DOISearch in Google Scholar

32. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71: 5423–34. doi: 10.1158/0008-5472.CAN-11-0367 Labidi-GalySI SisirakV MeeusP GobertM TreilleuxI BajardA Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer Cancer Res 2011 71 5423 34 10.1158/0008-5472.CAN-11-0367 Open DOISearch in Google Scholar

33. Ning F, Cole CB, Annunziata CM. Driving immune responses in the ovarian tumor microenvironment. Front Oncol 2021; 10: 604084–98. doi: 10.3389/fonc.2020.604084 NingF ColeCB AnnunziataCM Driving immune responses in the ovarian tumor microenvironment Front Oncol 2021 10 604084 98 10.3389/fonc.2020.604084 Open DOISearch in Google Scholar

34. Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. Front Immunol 2019; 10: 1782–97. doi: 10.3389/fimmu.2019.01782 NersesianS GlazebrookH ToulanyJ GranthamSR BoudreauJE Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer Front Immunol 2019 10 1782 97 10.3389/fimmu.2019.01782 Open DOISearch in Google Scholar

35. Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121: 3599–608. doi: 10.1182/blood-2012-04-425397 RomeeR FoleyB LenvikT WangY ZhangB AnkarloD NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17) Blood 2013 121 3599 608 10.1182/blood-2012-04-425397 Open DOISearch in Google Scholar

36. Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V, et al. Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers. Front Oncol 2020; 10: 566511–44. doi: 10.3389/fonc.2020.566511 LarionovaI TuguzbaevaG PonomaryovaA StakheyevaM CherdyntsevaN PavlovV Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers Front Oncol 2020 10 566511 44 10.3389/fonc.2020.566511 Open DOISearch in Google Scholar

37. Hoover AA, Hufnagel DH, Harris W, Bullock K, Glass EB, Liu E, et al. Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer. BMC Cancer 2020; 20: 970–85. doi: 10.1186/s12885-020-07450-8 HooverAA HufnagelDH HarrisW BullockK GlassEB LiuE Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer BMC Cancer 2020 20 970 85 10.1186/s12885-020-07450-8 Open DOISearch in Google Scholar

38. Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells 2020; 9: 1299–300. doi: 10.3390/cells9051299 NowakM KlinkM The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer Cells 2020 9 1299 300 10.3390/cells9051299 Open DOISearch in Google Scholar

39. Osborn G, Stavraka C, Adams R, Sayasneh A, Ghosh S, Montes A, et al. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clin Exp Immunol 2022; 209: 4–21. doi: 10.1093/cei/uxab020 OsbornG StavrakaC AdamsR SayasnehA GhoshS MontesA Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies Clin Exp Immunol 2022 209 4 21 10.1093/cei/uxab020 Open DOISearch in Google Scholar

40. Leary A, Tan D, Ledermann J. Immune checkpoint inhibitors in ovarian cancer: where do we stand? Ther Adv Med Oncol 2021; 13: 17588359211039899. doi: 10.1177/17588359211039899 LearyA TanD LedermannJ Immune checkpoint inhibitors in ovarian cancer: where do we stand? Ther Adv Med Oncol 2021 13 17588359211039899 10.1177/17588359211039899 Open DOISearch in Google Scholar

41. Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, et al. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma. Oncol Lett 2018; 15: 6457–68. doi: 10.3892/ol.2018.8101 ImaiY HasegawaK MatsushitaH FujiedaN SatoS MiyagiE Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma Oncol Lett 2018 15 6457 68 10.3892/ol.2018.8101 Open DOISearch in Google Scholar

42. Pawłowska A, Suszczyk D, Tarkowski R, Paduch R, Kotarski J, Wertel I. et al. Programmed death-1 receptor (PD-1) as a potential prognosis biomarker for ovarian cancer patients. Cancer Manag Res 2020; 12: 9691–709. doi: 10.2147/CMAR.S263010 PawłowskaA SuszczykD TarkowskiR PaduchR KotarskiJ WertelI Programmed death-1 receptor (PD-1) as a potential prognosis biomarker for ovarian cancer patients Cancer Manag Res 2020 12 9691 709 10.2147/CMAR.S263010 Open DOISearch in Google Scholar

43. Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016; 7: 1486–99. doi: 10.18632/oncotarget.6429 Darb-EsfahaniS KunzeCA KulbeH SehouliJ WienertS LindnerJ Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma Oncotarget 2016 7 1486 99 10.18632/oncotarget.6429 Open DOISearch in Google Scholar

44. Xu M, Zhang B, Zhang M, Liu Y, Yin FL, Liu X, et al. Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer. Oncol Lett 2016; 11: 2815–19. doi: 10.3892/ol.2016.4301 XuM ZhangB ZhangM LiuY YinFL LiuX Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer Oncol Lett 2016 11 2815 19 10.3892/ol.2016.4301 Open DOISearch in Google Scholar

45. Cai J, Wang D, Zhang G, Guo X. The role Of PD-1/PD-L1 axis in Treg development and function: Implications for cancer immunotherapy. Onco Targets Ther 2019; 12: 8437–45. doi: 10.2147/OTT.S221340 CaiJ WangD ZhangG GuoX The role Of PD-1/PD-L1 axis in Treg development and function: Implications for cancer immunotherapy Onco Targets Ther 2019 12 8437 45 10.2147/OTT.S221340 Open DOISearch in Google Scholar